These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 11489498)

  • 1. Doxorubicin bound to a HPMA copolymer carrier through hydrazone bond is effective also in a cancer cell line with a limited content of lysosomes.
    Ríhová B; Etrych T; Pechar M; Jelínková M; Stastný M; Hovorka O; Kovár M; Ulbrich K
    J Control Release; 2001 Jul; 74(1-3):225-32. PubMed ID: 11489498
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Doxorubicin release is not a prerequisite for the in vitro cytotoxicity of HPMA-based pharmaceuticals: in vitro effect of extra drug-free GlyPheLeuGly sequences.
    Ríhová B; Strohalm J; Hovorka O; Subr V; Etrych T; Chytil P; Pola R; Plocová D; Boucek J; Ulbrich K
    J Control Release; 2008 Apr; 127(2):110-20. PubMed ID: 18325618
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New HPMA copolymers containing doxorubicin bound via pH-sensitive linkage: synthesis and preliminary in vitro and in vivo biological properties.
    Etrych T; Jelínková M; Ríhová B; Ulbrich K
    J Control Release; 2001 May; 73(1):89-102. PubMed ID: 11337062
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Polymer conjugates of doxorubicin bound through an amide and hydrazone bond: Impact of the carrier structure onto synergistic action in the treatment of solid tumours.
    Etrych T; Subr V; Laga R; Ríhová B; Ulbrich K
    Eur J Pharm Sci; 2014 Jul; 58():1-12. PubMed ID: 24632485
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Properties of HPMA copolymer-doxorubicin conjugates with pH-controlled activation: effect of polymer chain modification.
    Chytil P; Etrych T; Konák C; Sírová M; Mrkvan T; Ríhová B; Ulbrich K
    J Control Release; 2006 Sep; 115(1):26-36. PubMed ID: 16899320
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The structure-dependent toxicity, pharmacokinetics and anti-tumour activity of HPMA copolymer conjugates in the treatment of solid tumours and leukaemia.
    Tomalova B; Sirova M; Rossmann P; Pola R; Strohalm J; Chytil P; Cerny V; Tomala J; Kabesova M; Rihova B; Ulbrich K; Etrych T; Kovar M
    J Control Release; 2016 Feb; 223():1-10. PubMed ID: 26708020
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antiproliferative effect of a lectin- and anti-Thy-1.2 antibody-targeted HPMA copolymer-bound doxorubicin on primary and metastatic human colorectal carcinoma and on human colorectal carcinoma transfected with the mouse Thy-1.2 gene.
    Ríhová B; Jelínková M; Strohalm J; St'astný M; Hovorka O; Plocová D; Kovár M; Dráberová L; Ulbrich K
    Bioconjug Chem; 2000; 11(5):664-73. PubMed ID: 10995209
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synergistic action of doxorubicin bound to the polymeric carrier based on N-(2-hydroxypropyl)methacrylamide copolymers through an amide or hydrazone bond.
    Ríhová B; Etrych T; Sírová M; Kovár L; Hovorka O; Kovár M; Benda A; Ulbrich K
    Mol Pharm; 2010 Aug; 7(4):1027-40. PubMed ID: 20524698
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Star structure of antibody-targeted HPMA copolymer-bound doxorubicin: a novel type of polymeric conjugate for targeted drug delivery with potent antitumor effect.
    Kovár M; Strohalm J; Etrych T; Ulbrich K; Ríhová B
    Bioconjug Chem; 2002; 13(2):206-15. PubMed ID: 11906257
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Overcoming multidrug resistance in Dox-resistant neuroblastoma cell lines via treatment with HPMA copolymer conjugates containing anthracyclines and P-gp inhibitors.
    Koziolová E; Janoušková O; Cuchalová L; Hvězdová Z; Hraběta J; Eckschlager T; Sivák L; Ulbrich K; Etrych T; Šubr V
    J Control Release; 2016 Jul; 233():136-46. PubMed ID: 27189135
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HPMA copolymers with pH-controlled release of doxorubicin: in vitro cytotoxicity and in vivo antitumor activity.
    Ulbrich K; Etrych T; Chytil P; Jelínková M; Ríhová B
    J Control Release; 2003 Feb; 87(1-3):33-47. PubMed ID: 12618021
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Polymer conjugates of the highly potent cytostatic drug 2-pyrrolinodoxorubicin.
    Studenovsky M; Ulbrich K; Ibrahimova M; Rihova B
    Eur J Pharm Sci; 2011 Jan; 42(1-2):156-63. PubMed ID: 21075206
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Star-shaped immunoglobulin-containing HPMA-based conjugates with doxorubicin for cancer therapy.
    Etrych T; Mrkvan T; Ríhová B; Ulbrich K
    J Control Release; 2007 Sep; 122(1):31-8. PubMed ID: 17631976
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HPMA copolymer conjugates with reduced anti-CD20 antibody for cell-specific drug targeting. I. Synthesis and in vitro evaluation of binding efficacy and cytostatic activity.
    Etrych T; Strohalm J; Kovár L; Kabesová M; Ríhová B; Ulbrich K
    J Control Release; 2009 Nov; 140(1):18-26. PubMed ID: 19632282
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pronounced Cellular Uptake of Pirarubicin versus That of Other Anthracyclines: Comparison of HPMA Copolymer Conjugates of Pirarubicin and Doxorubicin.
    Nakamura H; Koziolová E; Chytil P; Tsukigawa K; Fang J; Haratake M; Ulbrich K; Etrych T; Maeda H
    Mol Pharm; 2016 Dec; 13(12):4106-4115. PubMed ID: 27934482
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Water-soluble polymers for targeted drug delivery to human squamous carcinoma of head and neck.
    Nan A; Ghandehari H; Hebert C; Siavash H; Nikitakis N; Reynolds M; Sauk JJ
    J Drug Target; 2005 Apr; 13(3):189-97. PubMed ID: 16036307
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biodegradable star HPMA polymer-drug conjugates: Biodegradability, distribution and anti-tumor efficacy.
    Etrych T; Kovář L; Strohalm J; Chytil P; Ríhová B; Ulbrich K
    J Control Release; 2011 Sep; 154(3):241-8. PubMed ID: 21699933
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New HPMA copolymer-based drug carriers with covalently bound hydrophobic substituents for solid tumour targeting.
    Chytil P; Etrych T; Konák C; Sírová M; Mrkvan T; Boucek J; Ríhová B; Ulbrich K
    J Control Release; 2008 Apr; 127(2):121-30. PubMed ID: 18304673
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design of a multivalent galactoside ligand for selective targeting of HPMA copolymer-doxorubicin conjugates to human colon cancer cells.
    David A; Kopecková P; Minko T; Rubinstein A; Kopecek J
    Eur J Cancer; 2004 Jan; 40(1):148-57. PubMed ID: 14687799
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The structure of polymer carriers controls the efficacy of the experimental combination treatment of tumors with HPMA copolymer conjugates carrying doxorubicin and docetaxel.
    Šírová M; Strohalm J; Chytil P; Lidický O; Tomala J; Říhová B; Etrych T
    J Control Release; 2017 Jan; 246():1-11. PubMed ID: 27940304
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.